iiinova — where your digital self keeps evolving

Seaport Therapeutics @seaporttx.bsky.social · 09/10/2026

First presentation of detailed Phase 1 PK data for GlyphAgo at #ECNP2026, showing dose-dependent increases in agomelatine exposure, no food effect, reinforcing previously reported 6.8x bioavailability & 10x improved PK variability. bit.ly/4yJnEoG

000

Seaport Therapeutics @seaporttx.bsky.social · 07/10/2026

Important milestone: first patient dosed in our Phase 2a trial of GlyphAgo, a Glyphed oral prodrug of agomelatine, in adults w/#GAD & sleep disturbance. Trial is designed to evaluate effects on sleep & anxiety symptoms, w/topline data expected in early ’28 bit.ly/4jI9Cim

000

Seaport Therapeutics @seaporttx.bsky.social · 30/09/2026

To close #SuicidePreventionMonth, we welcomed survivor & speaker Kevin Berthia, who shared his story of hope & resilience. For #WSPD, we wrote letters to those struggling & held a moment of silence. These events inspire our mission to bring new medicines to patients & families

001

Seaport Therapeutics @seaporttx.bsky.social · 28/09/2026

Productive month engaging w/ the investor community: CEO Daphne Zohar at Goldman Sachs Life Science Symposium, plus CSO Michael Chen & CFO Lauren White at TD Cowen's Neuropsychiatry Summit, sharing highlights on our Glyph platform & pipeline. Event replays bit.ly/4jkikT

000

Seaport Therapeutics @seaporttx.bsky.social · 14/09/2026

Upcoming investor conferences: CEO @daphnezohar.bsky.social presents + joins neuro panel at Goldman Sachs Life Sciences Symposium. Mgmt fireside chat at TD Cowen Novel Mechanisms Summit. 1:1 mtgs at H.C. Wainwright Global Investment Conference & Deutsche Bank Healthcare Summit bit.ly/4j2Vwru

010

Seaport Therapeutics @seaporttx.bsky.social · 09/09/2026

Pleased to share positive topline results from our Ph1 driving simulation trial of GlyphAllo. Trial met its primary & key secondary endpoints: no next-morning driving impairment at either dose evaluated, providing addl support for GlyphAllo's differentiated overall profile in MDD bit.ly/4ikqScR

010

Seaport Therapeutics @seaporttx.bsky.social · 01/09/2026

Congrats to Co-Founder & CEO, Daphne Zohar for being named to MassLive's 25, which recognizes the most influential innovators in MA: bit.ly/4xzDku8 This follows her recent recognition by Forbes, highlighting her as a “drug development powerhouse.”

000

Seaport Therapeutics @seaporttx.bsky.social · 01/09/2026

This #SuicidePreventionMonth, we're reminded why our mission to develop potentially life-changing medicines for those w/#anxiety & #depression matters: 1B people globally live w/mental health conditions & those w/depression have a higher likelihood of suicidal ideation & attempts

000

Seaport Therapeutics @seaporttx.bsky.social · 31/08/2026

We're looking forward to upcoming investor conferences: Citi's 2026 Biopharma Back to School Conference (fireside chat w/ Seaport management on 9/9 at 1pm ET) & the 21st Annual Wells Fargo Healthcare Conference. Plus 1x1 meetings at both. Citi webcast: bit.ly/4qFU7ce

000

Seaport Therapeutics @seaporttx.bsky.social · 27/08/2026

The Seaport Crew enjoyed pickleball & paddleball at our summer outing in the Seaport! The team helped each other learn the sports, not so different from our day-to-day work, where we work collaboratively toward our mission of developing new treatments for #depression & #anxiety.

000

Seaport Therapeutics @seaporttx.bsky.social · 03/08/2026

Q2 results: successful IPO, continued pipeline execution w/previously reported positive Ph1 GlyphAgo data. Ahead: GlyphAgo Ph2 in GAD to begin 2H’26, GlyphAllo driving simulation data 2H’26 & Ph2b BUOY-1 topline MDD data 1H’27 & Glyph2BLSD on track bit.ly/3SazpEz

000

Seaport Therapeutics @seaporttx.bsky.social · 07/07/2026

At an internal poster session, employees learned about data presented at recent conferences, including GlyphAllo™ data presented at #ASCP. Sharing findings bridges clinical research & real-world impact, advancing our mission to develop new treatments for #depression & #anxiety.

000

Seaport Therapeutics @seaporttx.bsky.social · 23/06/2026

Our Co-Founder & CEO Daphne Zohar & Board Member Denice Torres were named to the #BLOC100 as Luminaires, recognized for contributions that will shape the future of biopharma. Proud to see their impact recognized, & leadership advancing progress for people living w/mental illness.

000

Seaport Therapeutics @seaporttx.bsky.social · 10/06/2026

CFO Lauren White & CSO Michael Chen, spoke at Goldman Sachs 47th Global Healthcare Conference, highlighting positive Ph1 MAD data for GlyphAgo™ & GlyphAllo™ updates, w/Ph2b BUOY-1 enrollment on track & topline data expected in H1 next year: bit.ly/3S385aU

000

Seaport Therapeutics @seaporttx.bsky.social · 09/06/2026

Listen tomorrow at 8:00AM ET for a fireside chat with CFO, Lauren White, & CSO, Michael Chen, at the Goldman Sachs 47th Annual Global Healthcare Conference. Our team will also participate in 1x1 meetings at the conference. Live & archived webcast: bit.ly/4e956Fn

000

Seaport Therapeutics @seaporttx.bsky.social · 08/06/2026

Today we reported Q1 '26 financial results & business updates. We advanced our clinical programs, including new MAD data from Ph1 trial of GlyphAgo & progress on GlyphAllo w/P2b data expected in 1H '27. Q1 results: bit.ly/4dWcOnj GlyphAgo data: bit.ly/43pTGIj

000

Seaport Therapeutics @seaporttx.bsky.social · 08/06/2026

New positive MAD data from Ph1 POC trial of GlyphAgo confirm favorable safety, tolerability, & PK w/repeat dosing, further reinforcing GlyphAgo’s ability to achieve therapeutic agomelatine exposure at doses projected to avoid liver enzyme elevations: bit.ly/43pTGIj

010

Seaport Therapeutics @seaporttx.bsky.social · 01/06/2026

We're participating in upcoming investor conferences in June, including the Goldman Sachs 47th Annual Global Healthcare Conference & UBS Virtual CNS Day. Seaport will participate in 1x1 meetings at both. Release: bit.ly/4nZNdxb Goldman webcast: bit.ly/4dOaCgb

000

Seaport Therapeutics @seaporttx.bsky.social · 19/05/2026

Proud to join #NAMIWalks this #MentalHealthAwarenessMonth to raise awareness, reduce stigma & support those impacted by mental illness - reinforcing our commitment to developing life-changing treatments for patients w/ #depression, #anxiety & other neuropsychiatric disorders

000

Seaport Therapeutics @seaporttx.bsky.social · 13/05/2026

Our CMO & AFSP board member Dr. Tony Loebel represented Seaport at #Lifesavers26. This #MHM2026 we're reminded suicide is 10th leading cause of death in US - 20x higher risk for those w/ #MDD. Proud to support & reinforce our work advancing #neuropsychiatric treatments.

000

Seaport Therapeutics @seaporttx.bsky.social · 27/04/2026

Excited to welcome Dr. Sharon Mates to our BOD! Dr. Mates was the Co-Founder, Chairman & CEO of Intra-Cellular where she grew the company from discovery & early innovation through commercialization of CAPLYTA & $14.6B acquisition by $JNJ bit.ly/4u5WOEl

120

Seaport Therapeutics @seaporttx.bsky.social · 21/04/2026

Proud to partner w/Life Science Cares to assemble 500+ snack packs & encouraging notes for local youth w/Youth Enrichment Services reflecting our value of service value & commitment to the wellbeing of our local community & those living w/ #depression, #anxiety & other #neuropsychiatric disorders.

000

Seaport Therapeutics @seaporttx.bsky.social · 09/04/2026

Celebrating 2 years! Big clinical milestones this year: initiation of our Ph2b BUOY‑1 trial of GlyphAllo in MDD & positive proof-of-concept Ph1 topline data for GlyphAgo. Proud of our progress & what’s ahead as we make a difference for those struggling w/ #depression & #anxiety.

011

Seaport Therapeutics @seaporttx.bsky.social · 02/04/2026

Positive Ph1 proof‑of‑concept topline results for GlyphAgo: 10x lower PK variability & 6.8x increase in bioavailability–exceeding our 2x target projected to mitigate liver exposure, a limitation that previously held back agomelatine's clinical use: bit.ly/3PBOkWV

032

Seaport Therapeutics @seaporttx.bsky.social · 25/03/2026

New paper in Science Translational Medicine features GlyphAllo as first triglyceride-mimetic prodrug to achieve therapeutically relevant drug levels in humans & further validates Glyph platform to effectively enable oral dosing. Paper: tinyurl.com/2mff276w Release: tinyurl.com/5hdenetm

010

Seaport Therapeutics @seaporttx.bsky.social · 03/03/2026

Seaport & Monash awarded up to $15M from ARPA‑H to advance GlyphCele™, supporting broader potential of Glyph platform to address diseases linked to gut lymphatic dysfunction (metabolic disease & pancreatic cancer) to reach patients beyond #CNS bit.ly/3MDnSLq

053

Seaport Therapeutics @seaporttx.bsky.social · 20/02/2026

Our team presented new meta-analysis at #ISCTM showing that more frequent clinician‑administered assessments have a strong association with magnitude of placebo response in #GAD trials – consistent with findings from our #MDD meta‑analysis. bit.ly/4ru1EL1

021

Seaport Therapeutics @seaporttx.bsky.social · 18/02/2026

We’re looking forward to our participation in three upcoming investor conferences in February & March: Leerink Partners Global Healthcare Conference, Oppenheimer 36th Annual Healthcare Life Sciences Conference, & Stifel 2026 Virtual CNS Forum. More here: bit.ly/4s1RvoF

011

Seaport Therapeutics @seaporttx.bsky.social · 12/02/2026

Co‑founder & Board Chair Dr Steve Paul joined BioCentury's podcast to discuss the past, present & future of neuropsychiatric drug development – from the depression space to potential of psychedelics - & what we’re building at Seaport w/our Glyph platform: bit.ly/4r2gRCy

bit.ly

Serendipity drives discovery in psychiatry, engineering gets it across the line, says Steve Paul

With disease biology still murky and trials notoriously noisy, psychiatry R&D is advancing fastest where teams can solve engineering problems. Delivery...

011

Seaport Therapeutics @seaporttx.bsky.social · 05/02/2026

Our Seaport team started the year w/a gathering to celebrate the holidays & reflect on our progress last year. It was great to connect as a team & we're excited to carry this energy through 2026 as we continue our mission to serve those impacted by #neuropsychiatric conditions.

000

Seaport Therapeutics @seaporttx.bsky.social · 13/01/2026

Co-founder & CEO @daphnezohar.bsky.social presented at #JPM26 sharing our recent progress & path forward as we tackle some of the biggest medical problems our population is facing today. Co-founders Steve Paul (Chair) & Michael Chen (CSO) joined for Q&A. #depression #anxiety #neuropsychiatry

021

Seaport Therapeutics @seaporttx.bsky.social · 05/01/2026

Our Co-founder & CEO, @daphnezohar.bsky.social, will present at #JPM26 on Jan. 12 at 9:30AM PT. She’ll be joined by Steve Paul, M.D., Co-founder & Chair & Michael Chen, Ph.D., Co-founder & CSO, during the Q&A portion of the presentation. bit.ly/3NsW6kt

022

Seaport Therapeutics @seaporttx.bsky.social · 23/12/2025

This year, we've made meaningful progress at Seaport from clinical milestones w/ the Ph2b BUOY‑1 study of GlyphAllo™ in #MDD (w/ or w/o anxious distress) & a Ph1 study of GlyphAgo™ for treatment of #GAD to moments together, made possible by our incredible team. #HappyHolidays!

000

Seaport Therapeutics @seaporttx.bsky.social · 11/12/2025

Today at 10AM ET our CFO, Lauren White, & CSO, Michael Chen, PhD, will present at the RBC Capital Markets Healthcare Private Company Conference. Members of our team will also participate in 1x1 meetings. Tune in: bit.ly/4a5zsYR Replays: bit.ly/3MokeEE

011

Seaport Therapeutics @seaporttx.bsky.social · 08/12/2025

#AES25: Data further validate Glyph’s ability to enhance oral bioavailability & expand therapeutic reach w/ successful application of Glyph to another class of clinically validated molecules previously held back by limitations Glyph’s designed to solve. bit.ly/44K0BwW

011

Seaport Therapeutics @seaporttx.bsky.social · 04/12/2025

Members of our management team will present at the 2025 RBC Capital Markets Healthcare Private Company Conference on Dec. 11 at 10AM ET & will participate in 1x1 meetings at the conference. Press release: bit.ly/3XTj7PT Live & archived webcast: seaporttx.com/news-papers/

011

Seaport Therapeutics @seaporttx.bsky.social · 01/12/2025

Team members joined @afspnational.bsky.social “Out of the Darkness” walk in Boston to raise awareness for suicide prevention. Our CMO, Tony Loebel, serves on AFSP's board, aligning w/ our mission to serve those w/ #mentalhealth conditions like #depression & #anxiety. Hear more from Tony!

010

Seaport Therapeutics @seaporttx.bsky.social · 26/11/2025

Our CEO @daphnezohar joined the Making Medicine podcast to talk biotech, policy, & Seaport’s mission. Her take on price controls? The real impact would fall on patients, who are at the center of our work at Seaport. Hear her response in the full episode: www.youtube.com/watch?v=ICsz...

youtube.com

Making Medicine ft. Daphne Zohar. Biotech Flywheels, Policy Risks, and the Future of Innovation.

YouTube video by Making Medicine

040

Seaport Therapeutics @seaporttx.bsky.social · 26/11/2025

#HappyThanksgiving! Ahead of the holiday, we assembled care packages for Rosie's Place - a women's shelter in Boston - & enjoyed time together at a holiday lunch. Giving back reminds us that we're here to serve those living w/ #mentalhealth conditions like #depression & #anxiety.

000

Seaport Therapeutics @seaporttx.bsky.social · 19/11/2025

Today Co-Founder & Board Chair Dr. Steve Paul joins Technology Innovation Studio’s Breakthrough Biotech Builders fireside chat on his role in the dev of CNS blockbusters Zyprexa®, Cymbalta® and Cobenfy™ (KarXT) which originated at PureTech (founded/led by @daphnezohar.bsky.social) luma.com/5rfgvqfd

luma.com

Breakthrough Biotech Builders: Session with Steve Paul · Luma

This discussion would be a private gathering designed to foster high-level dialogue and genuine connections in the area of biotech leadership. We hope that…

011

Seaport Therapeutics @seaporttx.bsky.social · 14/11/2025

Thanks to the NEVYs for nominating us for the Powerhouse Healthcare Company of the Year at the #NEVYs25Awards! Great progress this year w/ the launch of two clinical trials & we look forward to making a difference for those w/ #neuropsychiatric conditions: bit.ly/nevy25

000

Seaport Therapeutics @seaporttx.bsky.social · 11/11/2025

Tune in today at 10:00AM EST as our CFO, Lauren White, & CSO, Michael Chen, present at the Stifel 2025 Healthcare Conference. The team will also participate in 1x1 meetings while at the conference. Tune in: bit.ly/4oNTUBA Replay available here: bit.ly/43Nvu33

000

Seaport Therapeutics @seaporttx.bsky.social · 04/11/2025

Members of our management team will present at the Stifel 2025 Healthcare Conference on November 11 at 10:00AM ET. The team will also participate in 1x1 meetings during the conference. Press release: bit.ly/49x28cP Live & archived webcast here: seaporttx.com/news-papers/

000

Seaport Therapeutics @seaporttx.bsky.social · 31/10/2025

Happy Halloween! We had so much fun celebrating together w/ themed team costumes & plenty of laughs. These gatherings remind us how connection energizes our shared commitment to developing new medicines for people living w/ #neuropsychiatric conditions like #depression & #anxiety.

010

Seaport Therapeutics @seaporttx.bsky.social · 28/10/2025

Co-Founder & CEO, @daphnezohar.bsky.social joined an all-women Rare & Neuro Diseases panel at #USAIC25 (watch: bit.ly/3LcJkWg) & gave a shoutout to the Biotech CEO Sisterhood in her opening remarks (view: bit.ly/3X1WPKY). Join us at #USAIC26: bit.ly/4oEvmei

020

Seaport Therapeutics @seaporttx.bsky.social · 17/10/2025

“We Own It” is a core value of ours & captures our entrepreneurial spirit. Co-Founder & CEO, @daphnezohar.bsky.social, shows us how it's done. Named a Goldman Sachs Most Exceptional Entrepreneur, she inspires us to push boundaries so we can best serve those with #neuropsychiatric conditions.

020

Seaport Therapeutics @seaporttx.bsky.social · 10/10/2025

Board member, Denice Torres, shared her expertise on happiness, a core value & key to our work. We aim to increase happiness worldwide & develop novel medicines for #neuropsychiatric conditions. This #WorldMentalHealthDay, we’re reminded that happiness & mental health are linked.

000

Seaport Therapeutics @seaporttx.bsky.social · 09/10/2025

Members of our exec team joined Fierce Biotech’s #Fierce15 awards to celebrate our recognition, honoring our team's work developing new medicines for #depression & #anxiety. It's also a reflection of the strong momentum & growth since our launch last year. bit.ly/3VSOQQ7

021

Seaport Therapeutics @seaporttx.bsky.social · 08/10/2025

We convened top neuropsych experts, sell-side analysts, investors, & biopharma leaders for a unique roundtable discussion on the opportunities & excitement in #neuropsychiatry & what’s next as #MentalHealth conditions continue to impact millions globally. See below for some takeaways

011

Seaport Therapeutics @seaporttx.bsky.social · 25/09/2025

Tune in today at 11:45 AM ET to hear our CFO Lauren White & COO Eric Green present at the Oppenheimer Private Life Sciences Company Showcase. Live webcast: bit.ly/4nllNke & replay available on our website: seaporttx.com/news-papers/

010